FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

I spent years prosecuting traffickers of street drugs like meth and fentanyl, but the drug crisis that should most concern life sciences companies is a less visible illicit drug market: one that ...

Most emerging life sciences companies already understand the importance of thinking about the future patient. Leadership teams routinely model future treatment pathways, reimbursement environments, ...

Enrollment success begins long before a patient signs a consent form. As study eligibility criteria grow more complex, sites face increasing pressure to identify qualified participants while managing ...

In ophthalmic trials, operational execution has a direct impact on endpoint quality. Precision assessments often depend on specialized equipment, trained personnel, and strict adherence to visit ...

On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Dr. Ebrahim Delpassand, founder, chairman and CEO at RadioMedix, explains why ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” panelists discuss the funding opportunities and investor landscape for ...

It supports targeted glycan modulation without compromising cell culture performance or critical quality attributes. Increases galactosylation, shifting glycan profiles from G0F to G1F and G2F.